{"id":"W1974674483","doi":"10.1182/blood-2006-04-015560","title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Fms-Like Tyrosine Kinase 3; Tyrosine-kinase inhibitor; Chemotherapy; Adverse effect; Oncology; Pharmacology; Leukemia; Chemotherapy regimen; Cancer; Biology; Mutation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007543435,0.0009769263,0.001031949,0.0002668966,0.0002416246,0.0004978729,0.0004386918,0.0007176425,0.002669416],"category_scores_gemma":[0.0005436103,0.0002807512,0.0004898996,0.0002221317,0.0003712607,0.0004328619,0.0002040718,0.001771343,0.0004144959],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004743184,"about_ca_system_score_gemma":0.0006856113,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006080745,"about_ca_topic_score_gemma":0.001936012,"domain_scores_codex":[0.9998431,0.00007119979,0.000007188297,0.00002708068,0.0000162639,0.00003518315],"domain_scores_gemma":[0.9997365,0.00003786628,0.00004206416,0.00001482802,0.00001828232,0.000150466],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6748446,0.05940033,0.007837925,0.0007388078,0.0009602497,0.001158064,0.0003351625,0.00275015,0.08298568,0.0006452262,0.009566498,0.1587773],"study_design_scores_gemma":[0.6258888,0.3451504,0.01657424,0.00003240454,0.0003029414,0.0007837926,0.00004854742,0.002021878,0.003819827,0.0002373523,0.005113102,0.00002670063],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9930683,0.001609975,0.0004048934,0.0005564228,0.0001418754,0.001681761,0.0006835038,0.00006161997,0.001791576],"genre_scores_gemma":[0.9881769,0.001875478,0.001718493,0.00116022,0.0002181953,0.001977063,0.001941105,0.00001689846,0.002915712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002669416,"threshold_uncertainty_score":0.008930087,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02650563510070308,"score_gpt":0.3123375602894287,"score_spread":0.2858319251887256,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}